Raynaud’s

FDA Approves Drug to Treat Lupus

Good news for fellow Frosties with Lupus! HEALTH INDUSTRY MARCH 9, 2011, 6:22 P.M. ET Wall Street Journal The Food and Drug Administration approved a new lupus drug from Human Genome Sciences Inc. and GlaxoSmithKline PLC, marking the first new treatment for the autoimmune disease in more than 50 years.

2011-03-16T00:10:58-04:00March 9th, 2011|In The News|2 Comments

Sildenafil (Viagra) Reduces Raynaud’s Frequency in Patients with Scleroderma

    Modified-Release Therapy is Well Tolerated in Clinical Trial Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud’s phenomenon in patients with limited cutaneous systemic sclerosis (lcSSc), also known as scleroderma. The double-blind, placebo-controlled trial found that sildenafil was well tolerated with only some subjects experiencing minor

2011-03-08T10:21:29-05:00March 8th, 2011|In The News|Comments Off on Sildenafil (Viagra) Reduces Raynaud’s Frequency in Patients with Scleroderma
Go to Top